University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides ...

The Food and Drug Administration (FDA) has approved Tyzavan ™ (vancomycin injection, USP), a novel ready-to-infuse, room temperature stable formulation of vancomycin, for the treatment of various ...

Vancomycin appeared to top placebo for lowering Clostridioides difficile infection (CDI) recurrence rates in patients taking ...

Fecal microbiota transplantation (FMT) could be considered as first-line therapy for primary Clostridioides difficile infection (CDI).

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to-infuse formulation of vancomycin, ...

Fecal microbiota transplantation was not inferior to vancomycin for the treatment of primary Clostridioides difficile ...

In one of the most comprehensive real-world analyses to date, Danish researchers report that fecal microbiota transplantation ...

Glenmark's Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) is bioequivalent and therapeutically equivalent to the reference listed drug, ...

Vancomycin Hydrochloride for Injection had a market value of approximately $39.3 million for the 12 month period ending January 2025, per IQVIA. [Read more: Glenmark releases generic Travatan Z] ...

The administration of β-lactams prior to vancomycin is associated with reduced risk of in-hospital mortality among patients with sepsis, according to results of a study published in Clinical ...

A four-week treatment with oral vancomycin led to clinical remission in PSC-IBD patients, accompanied by significant shifts in gut microbiota, reduced inflammation, and altered bile acid and short ...

Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational ...